Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Part 1 (Open-label Extension)
\- Participants previously enrolled in the Phase II OLE study or Phase III controlled studies who meet the eligibility criteria for open-label etrolizumab for those studies as described in the protocol
Part 2 (Safety Monitoring)
You may not be if
Participants who transfer from Part 1 (OLE)
Completion of the 12-week safety follow-up prior to entering.
Part 1 (Open-label Extension)
Withdrawal of consent from and participant not compliant in the Phase II OLE study or any of the Phase III studies
Participant who discontinued etrolizumab/etrolizumab placebo prior to Week 10 or did not perform the Week 10 visit of the Phase III Studies GA28948, GA28949, GA29102, and GA29103
Participant who discontinued etrolizumab/etrolizumab placebo prior to Week 14 or did not perform the Week 14 visit of the Phase III Study GA28950
Any new, significant, uncontrolled condition
Clareo Health | Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
